Next 10 |
home / stock / nrbo / nrbo articles
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emer...
MIAMI, July 16, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emer...
The Dow Jones index closed lower by around 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern a...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow traded up 0.66% to 38,...
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected ...
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday. The Dow traded up 0.23% to 38,238.99 while ...
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) shares are trading higher Thursday after the company announced the U.S. Food and Drug Administration (F...
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market opening Thursday, ...
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares are trading lower in Friday's premarket session after ending Thursday's session wi...
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...
NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in...